No abstract

No abstract

Dear Editor, Reports on COVID-19 in children are limited. Despite new data emerging, and understanding of the disease improves rapidly, there are as yet several features and complications related to the disease that remain unknown. Herein, we report the first case of a child with chilblains and retinal vasculitis related to COVID-19. An 11-year-old patient arrived at the Dermatology Emergency Department with a 2-week history of asymptomatic plaques on his toes. He did not complain of fever, respiratory symptoms (as cough or dyspnoea), headache, malaise, sore throat, nasal congestion or diarrhoea. He had no history of family exposure, and he was taking strict social distancing measures due to the Spanish Government restrictions applied on 13 March 2020. Physical examination showed oedematous and erythematous to violaceous plaques on the dorsal toes of both feet (Fig. 1). These lesions were clinically compatible with chilblains. A nasopharyngeal sample was obtained, and a reverse transcription polymerase chain reaction (RT-PCR) was negative for SARS-CoV-2. Serologic tests (both immunochromatographic and chemiluminescence immunoassay) showed negative SARS-CoV-2 IgM with positive IgG antibodies. Complementary studies, including Author contributions Drs Quintana-Castanedo Feito-Rodr ıguez and Mayor-Ibarguren conceptualized and designed the study, coordinated and drafted the initial manuscript, and reviewed and revised the manuscript. Drs Fern andez-Alcalde, Granados-Fern andez, Montero-Vega and de Lucas-Laguna designed the data collection instruments, collected data, carried out the initial analyses, and reviewed and revised the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

BACKGROUND Raynaud's phenomenon (RP) is a clinical syndrome characterized by recurrent episodes of digital vasospasm triggered by exposure to physical and chemical agents or emotional stress. Although many pharmacologic treatments have been tested, there is still no cure or gold standard therapy. Botulinum toxin treatment has been proved to reduce pain and increase arterial blood flow in treated hands of adult patients with RP. OBJECTIVE The aim of this study is to evaluate the efficacy of botulinum toxin A on younger than 18-year-old patients with primary and secondary RP. MATERIALS AND METHODS A single-center prospective study was performed, including 8 patients aged 14 to 17 years who were clinically diagnosed with primary or secondary RP. BTX was injected into each hand without sedation or anesthetic blockade. The primary outcome was pain reduction after BTX injection. Pain intensity was evaluated at baseline and in the first follow-up. Secondary outcomes included variations in the number and severity of RP episodes after the BTX injection. RESULTS All patients stated significant pain reduction and decreased cold sensitivity, except one patient who did not feel any changes. No patients reported any loss of strength on thumb-index finger. CONCLUSION BTX injection is a simple, noninvasive, and cost-effective treatment alternative, offering an important nonsurgical therapeutic option for the pediatric population. It could also help optimize the dose of other treatments used in these patients. The most commonly observed positive effect is a reduction in the pain associated with RP attacks. Further studies are needed to confirm these results.

Segmental stiff skin syndrome is a rare genetic connective tissue disease, which is often misdiagnosed. High-frequency ultrasonography can represent a useful clinical adjunct in the differential diagnosis of this condition, in conjunction with the clinical and histopathological findings. Treatment options are limited and evidence is scarce. We present the clinical, sonographic and histological features of five paediatric patients diagnosed at our institution and discuss their response to treatment.